Aileron Therapeutics Inc.'s wider series E round of $48 million came as a result of upped attention from investors, thanks to "work that's gone on during the last 10 months," said Joseph Yanchik, CEO of the Cambridge, Mass.-based firm, which is developing stapled-peptide technology.